IDH2 is a novel diagnostic and prognostic serum biomarker for non-small-cell lung cancer

Jiang Jiang Li, Ruilei Li, Wenxiang Wang, Baihua Zhang, Xin Song, Chunfang Zhang, Yang Gao, Qianjin Liao, Ya He, Shuo You, Zheqiong Tan, Xiangjian Luo, Yueshuo Li, Min Tang, Xinxian Weng, Wei Yi, Shifang Peng, Shaohui Liu, Ying Tan, Ann M. BodeYa Cao

Research output: Contribution to journalArticlepeer-review

7 Scopus citations


Lung cancer is the most common leading cause of cancer-related death worldwide. Late diagnosis contributes to a high mortality rate and poor survival of this cancer. In our previous study, we found that IDH2 polymorphism rs11540478 is a risk factor for lung cancer. Here, we examined IDH2 protein expression in culture medium in which two non-small-cell lung cancer (NSCLC) cell lines, H460 and A549, were growing. We found that the IDH2 protein was elevated in the culture supernatant fraction in a time- and cell number-dependent manner. Next, we used ELISA methods to examine IDH2 protein level in serum from patients with NSCLC and healthy controls. We found that IDH2 protein levels in serum could distinguish NSCLC patients from healthy controls with an AUC (area under the curve) of 0.83 (95% confidence interval = 0.79–0.88). The IDH2 level was decreased in serum from NSCLC postsurgical patients compared with the paired presurgical serum. High serum IDH2 levels appear to correlate with poor survival in patients with NSCLC. These results suggest that IDH2 levels in the serum could be a new effective biomarker for the diagnosis and prognosis of NSCLC.

Original languageEnglish (US)
Pages (from-to)602-610
Number of pages9
JournalMolecular Oncology
Issue number5
StatePublished - May 2018

Bibliographical note

Funding Information:
This work was supported by The National Basic Research Program of China (No. 2011CB504305) and The Natural Science Foundation of Hunan Province (No. 14JJ3039).

Publisher Copyright:
© 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.


  • IDH2
  • non-small-cell lung cancer
  • serum biomarker


Dive into the research topics of 'IDH2 is a novel diagnostic and prognostic serum biomarker for non-small-cell lung cancer'. Together they form a unique fingerprint.

Cite this